1-3 of 3
Alan Rosen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Diverse Drug Combinations with an Eed Inhibitor Confer Context-Specific Benefit across Multiple Tumor Types

Jessie Hao-Ru Hsu, Sasha Borodovsky, Yanjun Wang, Maryann San Martin, Minhui Shen, Haley Woods, Alan Rosen, Sharan Bagal, Philip Rawlins, James Robinson, Erin Code, Laura Prickett, Andrew Bloecher
Journal: Blood
Blood (2021) 138 (Supplement 1): 2274.
https://doi.org/10.1182/blood-2021-150483
Published: 2021
Journal Articles

Combination Benefit of Capivasertib and Venetoclax in Preclinical Models of Diffuse Large B-Cell Lymphoma

Brandon Willis, India Neveras, Hannah Dry, Wendan Xu, Yang Li, Kevin Mongeon, Justine Roderick, Alan Rosen, Pavel Klener, Jr., Georg Lenz, Jerome Mettetal, Simon Barry
Journal: Blood
Blood (2021) 138 (Supplement 1): 1870.
https://doi.org/10.1182/blood-2021-153711
Published: 2021
Journal Articles

Identification of Novel Combination Therapies Active in BCL2 Inhibitor-Resistant Patient-Derived AML Models

Courtney L Andersen, PhD, Amanda L Christie, MS, Alan Rosen, MS, Kim Maratea, DVM, PhD, Maureen Hattersley, Jon Travers, PhD, Justin Cidado, PhD, Sai Pulukuri, PhD, Jamal Saeh, PhD, Edwin Clark, PhD, Corinne Reimer, PhD, Jerome Mettetal, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1273.
https://doi.org/10.1182/blood-2019-129475
Published: 2019